Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men

  title={Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men},
  author={Eberhard Nieschlag and Dorothee B{\"u}chter and Sigrid von Eckardstein and Katrin Abshagen and Manuela Simoni and Hermann M Behre},
  journal={Clinical Endocrinology},
To investigate the suitability of intramuscular testosterone undecanoate (TU) injections for substitution therapy in hypogonadal men. 
Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM – Nebido®)
Objective  To investigate the loading regimen for intramuscular (IM) testosterone undecanoate (Nebido®) to determine whether testosterone and bioavailable testosterone levels achieved correlate with
Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo‐controlled feasability study for male contraception
This study was designed to prove the efficacy of the long‐acting testosterone undecanoate ester (TU) alone or in combination with oral levonorgestrel (LNG) in a phase II clinical trial.
Testosterone replacement therapy
The aim of testosterone replacement therapy (TRT) is to improve symptoms and signs of testosterone deficiency including decreased libido, erectile dysfunction, depressed mood, anaemia, loss of muscle
[Androgen replacement therapy for hypogonadal men].
Male hypogonadism is a group of syndromes in clinic andrology characterized by complete or partial androgen deficiency, androgen replacement therapy should be adopted in all patients of primary hypog onadism and patients who do not have the need of having a child.
[Testosterone replacement: application and surveillance].
  • G. Popken
  • Medicine, Biology
    Der Urologe. Ausg. A
  • 2010
Regular clinical and chemical controls of effect, side effects and contraindications are essential along with long-term substitution in male hypogonadism.
Current topics in testosterone replacement of hypogonadal men.
  • E. Nieschlag
  • Medicine, Biology
    Best practice & research. Clinical endocrinology & metabolism
  • 2015
Treatment Options for a Patient Experiencing Pruritic Rash Associated with Transdermal Testosterone: A Review of the Literature
A 22‐year‐old man with hypogonadotropic hypogonadism was receiving monthly intramuscular injections of testosterone replacement therapy. The patient refused to self‐administer the injections because
Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
Compared with conventional testosterone enanthate or cypionate treatment requiring injection intervals of 2-3 weeks and resulting in supraphysiological serum testosterone levels, injections of TU at intervals of up to 3 months offer an excellent alternative for substitution therapy of male hypogonadism.


Long‐term substitution therapy of hypogonadal men with transscrotal testosterone over 7–10 years
To assess the quality of this new form of T substitution, hypogonadal men treated by transdermal T up to 10 years were followed and scrotal T patches were followed.
Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men
This investigation was performed to establish detailed data about the pharmacokinetics, pharmacodynamics, feasibility and side‐effects of subcutaneously implanted testosterone (T) pellets.
Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies.
The longer half-life and the smaller injection volume make TU in castor oil a strong candidate for further applications in substitution therapy and in trials for male contraception.
A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
It is concluded that single-dose injections of TU to hypogonadal men can maintain serum T concentration within the normal range for at least 7 weeks without immediately apparent side effects.
Comparative pharmacokinetics of testosterone esters
In replacing an endogenous hormone a safe general principle appears to be to mimic, as closely as possible, the normal concentrations of that hormone or its active metabolites. Following this
Prostate volume in testosterone‐treated and untreated hypogonadal men in comparison to age‐matched normal controls
The potential use of testosterone preparations for substitution therapy for ageing men and for male contraception, and the effect of testosterone therapy on the prostate in hypogonadal men are studied.
Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
The results of the first clinical trial with TB for male contraception indicate a different hormonal equilibrium and probably different susceptibility to feedback regulation of the responders compared to the nonresponders.
Pharmacology, pharmacokinetics and effects/side-effects of different androgen preparations
The different testosterone preparations available or under investigation for substitution are outlined, the current status of monitoring testosterone therapy is summarized, and the different risks and benefits are summarized.
Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester.
In conclusion, single injections of 600 mg TB in hypogonadal patients show favorable pharmacokinetics and pharmacodynamics and this new long-acting T ester is a promising new agent for substitution therapy of male Hypogonadism and for male contraception.
Treatment of male hypogonadism with testosterone enanthate.
The close parallel of the FSH response to that of LH suggests that testosterone is the major physiological inhibitor of FSH as well as of LH, and several dosage regimens of testosterone enanthate appeared to be the most effective of those tested in terms of suppression of the serum LH concentration to normal and infrequency of administration.